Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 464

1.

Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma.

Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST.

Blood. 2002 Feb 15;99(4):1405-10.

2.

Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met.

van der Voort R, Taher TE, Wielenga VJ, Spaargaren M, Prevo R, Smit L, David G, Hartmann G, Gherardi E, Pals ST.

J Biol Chem. 1999 Mar 5;274(10):6499-506.

3.

A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.

Hov H, Holt RU, Rø TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen JG, Waage A, Sundan A, Børset M.

Clin Cancer Res. 2004 Oct 1;10(19):6686-94.

4.

Hepatocyte growth factor exerts a proliferative effect on oval cells through the PI3K/AKT signaling pathway.

Okano J, Shiota G, Matsumoto K, Yasui S, Kurimasa A, Hisatome I, Steinberg P, Murawaki Y.

Biochem Biophys Res Commun. 2003 Sep 19;309(2):298-304.

PMID:
12951049
5.
6.

High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity.

Seidel C, Børset M, Hjertner O, Cao D, Abildgaard N, Hjorth-Hansen H, Sanderson RD, Waage A, Sundan A.

Blood. 2000 Nov 1;96(9):3139-46.

7.
8.

Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.

Ye M, Hu D, Tu L, Zhou X, Lu F, Wen B, Wu W, Lin Y, Zhou Z, Qu J.

Invest Ophthalmol Vis Sci. 2008 Feb;49(2):497-504. doi: 10.1167/iovs.07-0975.

PMID:
18234991
9.
10.

A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats.

Ueda H, Nakamura T, Matsumoto K, Sawa Y, Matsuda H, Nakamura T.

Cardiovasc Res. 2001 Jul;51(1):41-50.

PMID:
11399246
11.
12.
13.

MUC20 suppresses the hepatocyte growth factor-induced Grb2-Ras pathway by binding to a multifunctional docking site of met.

Higuchi T, Orita T, Katsuya K, Yamasaki Y, Akiyama K, Li H, Yamamoto T, Saito Y, Nakamura M.

Mol Cell Biol. 2004 Sep;24(17):7456-68.

14.
15.

c-Met signaling promotes IL-6-induced myeloma cell proliferation.

Hov H, Tian E, Holien T, Holt RU, Våtsveen TK, Fagerli UM, Waage A, Børset M, Sundan A.

Eur J Haematol. 2009 Apr;82(4):277-87. doi: 10.1111/j.1600-0609.2009.01212.x. Epub 2009 Jan 6.

16.

Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation.

Dhodapkar MV, Abe E, Theus A, Lacy M, Langford JK, Barlogie B, Sanderson RD.

Blood. 1998 Apr 15;91(8):2679-88.

17.

Soluble syndecan-1 promotes growth of myeloma tumors in vivo.

Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, Epstein J, Sanderson RD.

Blood. 2002 Jul 15;100(2):610-7.

18.

Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups.

Bisping G, Kropff M, Wenning D, Dreyer B, Bessonov S, Hilberg F, Roth GJ, Munzert G, Stefanic M, Stelljes M, Scheffold C, Müller-Tidow C, Liebisch P, Lang N, Tchinda J, Serve HL, Mesters RM, Berdel WE, Kienast J.

Blood. 2006 Mar 1;107(5):2079-89. Epub 2005 Nov 8.

20.

Supplemental Content

Support Center